. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Nat Rev Mol Cell Biol. 2016 Aug 24;17(11):679–690. doi: 10.1038/nrm.2016.93

Table 2.

Clinical trials of sirtuin-activating compounds (2000–2016)

Sirtuin-activating compound	Phase I (safety)	Phase II (safety and efficacy)	Phase III–IV (pivotal and post-marketing)
Resveratrol or trans-resveratrol	Cardiovascular: NCT01564381, NCT02415114, NCT02616822, NCT01842399, NCT01185067 Cancer: NCT00256334 Diabetes: NCT01677611, NCT02502253 Neuropathy: NCT01339884, NCT01126229, NCT01321151, NCT01640197	Cardiovascular: NCT01449110, NCT01564381, NCT01842399, NCT02409537, NCT01615445, NCT02062190 Diabetes: NCT02114892, NCT01158417, NCT02549924, NCT02247596, NCT01451918, NCT01714102, NCT02216552 Neuropathy: NCT01339884, NCT02621554, NCT01504854, NCT02062190	Cardiovascular: NCT01914081 Pulmonary: NCT02245932 Diabetes: NCT01997762, NCT02244879, NCT02219906, NCT02216552, NCT02766803 Inflammation: NCT01492114, NCT02244879, NCT02475564, NCT02433925, NCT02130440 Neuropathy: NCT02621554, NCT02336633, NCT00678431, NCT01219244
SRT2104	Cardiovascular: NCT01031108, NCT01702493 Diabetes: NCT01031108 Inflammation: NCT01453491, NCT01014117	Inflammation: NCT01154101 Diabetes: NCT01018017, NCT00937326	None
Nicotinamide riboside	Phamacokinetics: NCT02689882, NCT02300740, NCT02721537, NCT02712593, NCT02191462 Cardiovascular: NCT02678611	Diabetes: NCT02303483	None

Clinical trials of sirtuin-activating compounds are listed in the table with their unique ClinicalTrials.gov identifier number. At the time of this publication, we excluded studies with unknown status.